Abstract
Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the “targeted therapies”, particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.
Keywords: Renal cell carcinoma, tyrosine kinase inhibitor, antiangiogenic agents, ASCO 2007, combination regime, targeted therapies
Reviews on Recent Clinical Trials
Title: Novel Therapeutic Options in Metastatic Renal Cancer – Review and Post ASCO 2007 Update
Volume: 3 Issue: 3
Author(s): Stephan Kruck, Markus A. Kuczyk, Georgios Gakis, Mario W. Kramer, Arnulf Stenzl and Axel S. Merseburger
Affiliation:
Keywords: Renal cell carcinoma, tyrosine kinase inhibitor, antiangiogenic agents, ASCO 2007, combination regime, targeted therapies
Abstract: Cytokine-based therapeutic approaches using interferon (IFN) and interleukin 2 (IL-2) were conventionally applied for the treatment of progressive RCC. Caused by the limited effectiveness of cytokine-based approaches in advanced renal cell carcinoma, new substances were needed. Among these, the “targeted therapies”, particularly the group of the tyrosine kinase inhibitors, are of main interest. At present, multikinase inhibitors and antiangiogenic agents (VEGFR, PDGFR-beta, and mTOR) are used in first- and second-line therapies of metastatic RCC in various clinical studies. This review presents and discusses the effectiveness of the most frequently used substances in mono- or combination regimes based on current data of the ASCO 2007.
Export Options
About this article
Cite this article as:
Kruck Stephan, Kuczyk A. Markus, Gakis Georgios, Kramer W. Mario, Stenzl Arnulf and Merseburger S. Axel, Novel Therapeutic Options in Metastatic Renal Cancer – Review and Post ASCO 2007 Update, Reviews on Recent Clinical Trials 2008; 3 (3) . https://dx.doi.org/10.2174/157488708785700311
DOI https://dx.doi.org/10.2174/157488708785700311 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Therapies in Head and Neck Cancer: Past, Present and Future
Reviews on Recent Clinical Trials Microparticles: From Biogenesis to Biomarkers and Diagnostic Tools in Cardiovascular Disease
Current Stem Cell Research & Therapy Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines
Current Pharmaceutical Design The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Recent Inventions on Receptor Tyrosine Kinase RET Modulation
Recent Patents on Biotechnology The Influence of Diabetes in the Pathogenesis and the Clinical Course of Hepatocellular Carcinoma: Recent Findings and New Perspectives
Current Diabetes Reviews Macrophage-Assisted Inflammation and Pharmacological Regulation of the Cholinergic Anti-Inflammatory Pathway
Current Medicinal Chemistry Efficacy of PD-1 or PD-L1 Inhibitors and Central Nervous System Metastases in Advanced Cancer: A Meta-Analysis
Current Cancer Drug Targets Relevance of Micrometastases and Targeting the Bone Marrow Niche with Zoledronic Acid in Breast Cancer
Current Cancer Therapy Reviews Recent Advances in Medicinal Chemistry of Sulfonamides. Rational Design as Anti-Tumoral, Anti-Bacterial and Anti-Inflammatory Agents
Mini-Reviews in Medicinal Chemistry Role of the Non-Receptor Tyrosine Kinase Fes in Cancer
Current Medicinal Chemistry Curcumin: Powerful Immunomodulator from Turmeric
Current Immunology Reviews (Discontinued) Understanding and Targeting Osteoclastic Activity in Prostate Cancer Bone Metastases
Current Molecular Medicine Immunotherapy and Targeted Therapy Combinations in Renal Cancer
Current Clinical Pharmacology Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Current Pharmaceutical Design MicroRNAs in Leukemias: Emerging Diagnostic Tools and Therapeutic Targets
Current Drug Targets Midkine in Inflammatory and Toxic Conditions
Current Drug Delivery The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets Emerging Trends in Endometriosis Treatment - Review
Current Women`s Health Reviews Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets